ライフサイエンスコーパス: i.d.

1 sing Ascentis Express C18 column (50mmx2.1mm i.d.) packed with 2mum porous shell particles.

2 umn used was an XBridge C18 column (50x2.1mm i.d., 2.5microm particle size), and separation was perfo

3 A fused-core Kinetex C18 column (50x2.1mm i.d.; 2.6mum) was used for the analysis.

4 e was packed into a glass column (1.8 x 0.5 (i.d.) cm) and used in on-line chromatographic system.

5 e was packed into a glass column (1.8 x 0.5 (i.d.) cm) and used in the on-line chromatographic determ

6 After i.d. injection, these mice reliably develop skin graft-v

7 hibited significantly increased firing after i.d. SLIGRL-NH(2) for 9 min, to partial (25%) tachyphyla

8 m the skin to lymph nodes was observed after i.d., but not after s.c., inoculations, we used the latt

9 cterial dose influenced mouse survival after i.d. but not s.c. inoculation.

10 After an i.d. challenge, 15 of 16 mice who were inoculated with p

11 dministration of plasmid DNA by the i.m. and i.d. routes.

12 nce oligodeoxynucleotide conjugate, i.n. and i.d. IT delivery were similarly effective in modulating

13 Peritoneal and i.d. tumor models are suitable for studying hypoxia in m

14 ypoxia in disseminated peritoneal tumors and i.d. tumors were similar.

15 Oral administration b.i.d. of R115777 to nude mice bearing s.c. tumors at dose

16 asing doses of morphine (5-25 mg/kg, s.c., b.i.d.) and then maintained at 25 mg/kg (b.i.d.) for 4-7 d

17 mg q.d. for 3 days, or 600 mg twice daily (b.i.d.) for 3 days, or a single dose of fluconazole 150 mg

18 q.d.) (251); netarsudil 0.02% twice a day (b.i.d.) (254); or timolol 0.5% b.i.d.

19 =2 hours before surgery, then twice a day (b.i.d.) until hospital discharge or for up to 7 days.

20 ce daily (q.d.), timolol 0.5% twice a day (b.i.d.), and (ROCKET-2 only) netarsudil 0.02% b.i.d.

21 doses of 237 micromol/kg/day twice a day (b.i.d.), there was serious proximal tubule damage versus 4

22 4 groups: posaconazole 400 mg twice a day (b.i.d.); benznidazole 200 mg + placebo b.i.d.; benznidazol

23 r CEP-5214 to CD-1 mice at 23.8 mg/kg/dose b.i.d. resulted in a reversible inhibition of VEGF-R2/FLK-

24 .o. of CEP-7055 at 2.57 to 23.8 mg/kg/dose b.i.d. resulted in dose-related reductions in neovasculari

25 P-7055 at doses of 11.9 to 23.8 mg/kg/dose b.i.d. resulted in significant inhibition (50-90% maximum

26 d. (n = 31) or BUD/F 200/6 two inhalations b.i.d. (n = 29).

27 er a high dose BDP/F 100/6 two inhalations b.i.d. (n = 31) or BUD/F 200/6 two inhalations b.i.d. (n =

28 er, we show that rifampin (75 or 100 mg/kg b.i.d. for 3 d, intraperitoneal) suppressed allodynia indu

29 mal survival after oral dosing at 25 mg/kg b.i.d. for 5 and 15 days.

30 , b.i.d.) and then maintained at 25 mg/kg (b.i.d.) for 4-7 days.

31 r providing >99% inhibition at 12.5 mg/kg (b.i.d., orally) in the Leishmania infantum hamster model.

32 odels of contact hypersensitivity (1 mg/kg b.i.d.) and house dust (20 mg/kg q.d.) when dosed orally.

33 crease in weight gain observed at 36 mg/kg b.i.d.).

34 nserin (3 mg/kg), or haloperidol (1 mg/kg) b.i.d. 30 min before PCP (2 mg/kg, b.i.d.) for 7 days (day

35 mg/kg) b.i.d. 30 min before PCP (2 mg/kg, b.i.d.) for 7 days (day1-7), followed by a 7-day washout (

36 toneal injection of TRK820 (0.1-10 mug/kg, b.i.d.) significantly inhibited tumor growth by suppressin

37 mice when administered orally at 25 mg/kg, b.i.d., for 4 days.

38 161 600 mg q.d. (85.7%), and VT1161 600 mg b.i.d. (78.6%) groups versus the fluconazole group (62.5%)

39 bleeding was lower with dabigatran 110 mg b.i.d. (aHR: 0.60, 95% CI: 0.37 to 0.93) compared with war

40 or placebo (n=2), the second cohort 40 mg b.i.d. (n=6) or placebo (n=2), and the third cohort 40 mg

41 0 mg + placebo b.i.d.; benznidazole 200 mg b.i.d. + posaconazole 400 mg b.i.d.; or placebo 10 mg b.i.

42 on PPI and the dose was increased to 40 mg b.i.d. 31 consecutive patients with typical reflux symptom

43 in groups A and C; 4 to 6 ng/mL and 500 mg b.i.d. in group B.

44 MMF dosing were 5 to 7 ng/mL and 1,000 mg b.i.d. in groups A and C; 4 to 6 ng/mL and 500 mg b.i.d. i

45 The target asenapine dosage was 10 mg b.i.d. in the open-label period but could be titrated down

46 One group received sodium naproxen 550 mg b.i.d. plus placebo for 7 days, while the other group rece

47 ther group received sodium naproxen 550 mg b.i.d. plus rebamipide 100 mg b.i.d.

48 saconazole 400 mg b.i.d.; or placebo 10 mg b.i.d. T. cruzi deoxyribonucleic acid was detected by RT-P

49 diabetic subjects taking metformin 850 mg b.i.d. versus placebo.

50 sustained-release bupropion (up to 200 mg b.i.d.) (N=21) to patients receiving placebo (N=19).

51 ither placebo capsules + AFS or LDD (20 mg b.i.d.) + AFS.

52 fen (LDF) alone, 50 mg q.d.; 2) SDD (20 mg b.i.d.) alone; or 3) a combination of SDD plus LDF (combin

53 , followed by maintenance on placebo (0 mg b.i.d.) and active ibudilast (50 mg b.i.d.).

54 However, Org 26576 (100-300 mg b.i.d.) did not confirm these results.

55 ces: sequence A (n = 15) Org 26576 (100 mg b.i.d.) for 3 weeks, followed by a 2-week placebo crossove

56 = 18) Org 26576 flexible dose (100-300 mg b.i.d.) for 3 weeks, then 5 weeks placebo; sequence D (n =

57 l human laboratory efficacy of IBUD (50 mg b.i.d.) on primary measures of subjective response to alco

58 ee months of rosiglitazone treatment (4 mg b.i.d.) on whole-body insulin sensitivity and in vivo peri

59 icotinic receptor PAM JNJ-39393406 (100 mg b.i.d.) or placebo (double-blind, counter-balanced).

60 s treated with either vildaglipitin (50 mg b.i.d.) or placebo for 10 days using a double-blind, place

61 PF-5190457 (100 mg b.i.d.) reduced alcohol craving during the cue-reactivity

62 Org 26576 (100 mg b.i.d.) was superior to placebo in treating symptoms of ad

63 (placebo/0 mg b.i.d., 50 mg b.i.d., 100 mg b.i.d.).

64 followed by 3 weeks Org 26576 (100-300 mg b.i.d.).

65 (0 mg b.i.d.) and active ibudilast (50 mg b.i.d.).

66 cebo followed by 3 weeks Org 26576 (100 mg b.i.d.); sequence C (n = 18) Org 26576 flexible dose (100-

67 ith PF-5190457 (placebo/0 mg b.i.d., 50 mg b.i.d., 100 mg b.i.d.).

68 human study with PF-5190457 (placebo/0 mg b.i.d., 50 mg b.i.d., 100 mg b.i.d.).

69 ., aHR: 0.24, 95% CI: 0.08 to 0.56; 150 mg b.i.d., aHR: 0.08, 95% CI: 0.01 to 0.40).

70 as seen with both dabigatran doses (110 mg b.i.d., aHR: 0.24, 95% CI: 0.08 to 0.56; 150 mg b.i.d., aH

71 s lower with both dabigatran doses (110 mg b.i.d., aHR: 0.30, 95% CI: 0.18 to 0.49; 150 mg b.i.d., aH

72 ., aHR: 0.30, 95% CI: 0.18 to 0.49; 150 mg b.i.d., aHR: 0.40, 95% CI: 0.21 to 0.70).

73 idence interval [CI]: 0.65 to 0.95; 150 mg b.i.d., aHR: 0.57, 95% CI: 0.40 to 0.80), when compared wi

74 y lower with both dabigatran doses (110 mg b.i.d., propensity-match group stratified hazard ratio [aH

75 dazole 200 mg b.i.d. + posaconazole 400 mg b.i.d.; or placebo 10 mg b.i.d. T. cruzi deoxyribonucleic

76 d., 59% (149/253, ROCKET-2) for netarsudil b.i.d., and 8% (17/208, ROCKET-1) to 11% (27/251, ROCKET-2

77 17.9 mm Hg for netarsudil q.d., netarsudil b.i.d., and timolol, respectively, over 12 months.

78 24 h after induction of MR (60 mg/kg p.o. b.i.d.) and continued for three months.

79 Two doses of VEGFR2-TKI (25 mg/kg, p.o., b.i.d.) resulted in a decrease of V(b) to 1.3 +/- 0.3%.

80 P.o. administration (q.d. or b.i.d.) of CP-724,714 inhibits the growth of erbB2-overexp

81 d with 40 mg pantoprazole (PPI) or placebo b.i.d. was performed.

82 ay (b.i.d.); benznidazole 200 mg + placebo b.i.d.; benznidazole 200 mg b.i.d. + posaconazole 400 mg b

83 Immunostimulation by i.d. LT(G33D) is explained by its ability to induce migr

84 Fused silica capillaries (i.d. 50 microm, o.d. 360 microm) are employed as the dig

85 ized on the inner wall of a glass capillary (i.d. 0.8 mm, length = 5-15 cm).

86 d that lowest flow rates and smallest column i.d. gave the highest relative signal.

87 mpounds are observed to increase with column i.d., suggesting an increase in packing density.

88 renteral vaccines in general and for current i.d. vaccine development in particular.

89 f a ring electrode ion guide with decreasing i.d. and with a superimposed dc potential gradient along

90 cale containers in which the inner diameter (i.d.) and surface chemistry can be systematically and in

91 specifically a 20 m, 100 mum inner diameter (i.d.) capillary column with a 0.4 mum film thickness to

92 Using 1.5 microm inner diameter (i.d.) capillary columns, hydrodynamically injecting femt

93 00 psi) for packed 10-microm-inner diameter (i.d.) columns.

94 2 to 2 microL/min and column inner diameter (i.d.) from 25 to 75 microm on the relative signal obtain

95 OP) capillary column with an inner diameter (i.d.) of 28 mum and using an on-capillary admittance det

96 interface featuring a large inner diameter (i.d.) separation capillary, and a detachable small i.d.

97 ditions of natural route of challenge (i.e., i.d. inoculation), the immune response has the capacity

98 Employing i.d. inoculation to model sand fly transmission of paras

99 s were the dominant infected cells following i.d., but not s.c. or i.p., inoculation.

100 d acute cellular responses in mice following i.d. inoculation of the ear, subcutaneous (s.c.) inocula

101 uch-evoked scratching was observed following i.d. 5-HT (5-hydroxytryptamine), a protease-activated re

102 IgG-secreting cells were produced following i.d. immunization.

103 uvant is a safe, well-tolerated adjuvant for i.d. vaccination in humans and results in significant cu

104 aser illumination of skin as an adjuvant for i.d. vaccination with advantages over traditional adjuva

105 Ag-specific Abs compared with one of six for i.d. and two of six for i.l. routes.

106 r the independent identically distributed (i.i.d.) background model.

107 f independent and identically distributed (i.i.d.) draws does not come from a specified probability d

108 f independent and identically distributed (i.i.d.) random variables, i.e., a Bernoulli sequence.

109 um of independent identically distributed (i.i.d.) random variables.

110 s independent and identically distributed (i.i.d.) samples from the multivariate normal distribution.

111 measurement noise (input-dependent or non-i.i.d.) and anisotropic kernel functions, which are the tw

112 distribution function for the given set of i.i.d. draws.

113 adhesion events revealed violation of the i.i.d. assumption, depending on the receptor-ligand system

114 y marginalizing the 4( t ) patterns of the i.i.d. model to observed and expected parsimony counts, th

115 Rabbits immunized i.d. with 10 mug of rPA displayed 100% protection from a

116 they traverse fused-silica tubing ranging in i.d. from 25 to 75 microm.

117 etween the FAIMS exit and a capillary inlet (i.d. = 0.5 mm).

118 Intradermal (i.d.) immunization is a promising route of vaccine admin

119 Intradermal (i.d.) immunization of mice with recombinant PspA in comb

120 Intradermal (i.d.) infection with IOE established mild, self-limited

121 Intradermal (i.d.) injection of the PAR-2 agonist SLIGRL-NH(2) in the

122 Following acute intradermal (i.d.) injection of histamine in the rostral back, mechan

123 IVM of popliteal LNs after intradermal (i.d.) injection of bacteria in the footpad revealed incr

124 tive immunity in macaques after intradermal (i.d.) or intramuscular (i.m.) delivery of 0.5 to 1 mg of

125 We developed an intradermal (i.d.) injection model in which CD8+ T (OT-I) cells that

126 termine its efficacy against an intradermal (i.d.) or intranasal (i.n.) challenge with vaccinia virus

127 from intraperitoneal (i.p.) and intradermal (i.d.) challenge by L. interrogans serovar Copenhageni st

128 eminated peritoneal disease and intradermal (i.d.) growing tumors.

129 ared were intranasal (i.n.) and intradermal (i.d.) inoculation of the Francisella tularensis live vac

130 of vaccine by microneedle-based intradermal (i.d.) delivery or intramuscular (i.m.) injection using c

131 ty after transcutaneous (t.c.), intradermal (i.d.), and intramuscular (i.m.) administration of a triv

132 luated single versus concurrent intradermal (i.d.) and intramuscular (i.m.) vaccinations as a DNA-pri

133 Dorsal intradermal (i.d.) administration of AYP elicited intense scratching

134 here are few safe and effective intradermal (i.d.) adjuvants.

135 transmitted in nature following intradermal (i.d.) deposition of parasites by the bite of an infected

136 ous report where we implemented intradermal (i.d.) inoculations to study bacterial dissemination duri

137 In A. nancymaae, intradermal (i.d.) immunization with chimera plus single-mutant heat-

138 The intradermal (i.d.) injection of LPS into gp49B1-null (gp49B-/-) but n

139 Here, we investigated the intradermal (i.d.) or sublingual (s.l.) delivery of CFA/I fimbrial an

140 by the intranasal (i.n.) vs the intradermal (i.d.) route.

141 ized with Ag-pulsed DC by i.v., intradermal (i.d.), or intralymphatic (i.l.) injection.

142 of IpaB and IpaD administered intradermally (i.d.) with a double-mutant of the Escherichia coli heat-

143 th 1.2 mg of DNA administered intradermally (i.d.; group A), 1.2 mg of DNA administered intramuscular

144 er 1800 micro g both i.m. and intradermally (i.d.); 9 of 12 patients had humoral (n = 6) and/or T-cel

145 t-knockout (KO) mice infected intradermally (i.d.) or intranasally (i.n.) with LVS succumbed to infec

146 s jet injection [i.m. or i.m./intradermally (i.d.)] in 14 volunteers.

147 ed with LVS DeltacapB i.n. or intradermally (i.d.) developed humoral and cellular immune responses co

148 to mice infected intraperitoneally with IOE, i.d. infection stimulated a stronger protective type-1 c

149 olithic capillary columns (25 cm x 10 microm i.d.) with integrated nanoESI emitters have been develop

150 and Rhodamine 6G, are obtained in 100 microm i.d. fused-silica capillaries under CE conditions using

151 r that moves through a capillary (100 microm i.d.) at a speed approximately 20 cm/s, under laminar fl

152 icides using capillary columns of 100-microm i.d. packed with a 5-microm octadecyl silica (ODS) stati

153 ylate) monoliths were prepared in 150 microm i.d. capillaries using novel binary porogenic solvents c

154 into fused-silica capillaries (50-150-microm i.d.) to form affinity chromatography columns.

155 ormance of high-efficiency 70 cm x 20 microm i.d. silica-based monolithic capillary LC columns.

156 microm i.d. x 360 microm o.d. and 20 microm i.d. x 360 microm o.d. capillaries within the flow rate

157 with a small dispensing aperture (20-microm i.d.) by constriction of a cylindrical piezoelectric ele

158 were achieved in CEC on a 64 cm x 25 microm i.d. sol-gel ODS open tubular column.

159 when passed through tubing with a 25-microm i.d. and a length of 100 cm.

160 Fused-silica capillary LC columns (25-microm i.d.) with 3-microm-i.d. integrated electrospray emitter

161 s (bPAECs) in microbore tubing of 250-microm i.d. are described.

162 ry, to 5-10 microm, which for a 20-30 microm i.d. capillary results in stable electrospray at approxi

163 ly useful for interfacing narrow (<30 microm i.d.) capillaries and low flow rates (<100 nL/min).

164 ht parallel channels (10 mm long, 360 microm i.d.) connected via external fused-silica capillaries.

165 thick tissue cross section into a 50 microm i.d. capillary where the tissue was solubilized with a s

166 column) were achieved on a 50 cm x 50 microm i.d. column using polycyclic aromatic hydrocarbons and a

167 pray and excellent performance for 50 microm i.d. x 360 microm o.d. and 20 microm i.d. x 360 microm o

168 The system uses 50 microm i.d. x 40-200 cm fused-silica capillaries packed with 1.

169 analysis times when capillaries of 50-microm i.d. or smaller are used.

170 spectrometry (LC-MS/MS) analyses, 75 microm i.d. x 14 cm capillary columns were interfaced with a co

171 rradiated at 365 nm for 5 min in a 75-microm i.d. capillary to prepare a porous monolithic sol-gel co

172 30-cm-long fused-silica capillary (75-microm i.d.) with dopamine, catechol, and ascorbic acid serving

173 monoliths were synthesized inside 75-microm i.d., UV-transparent fused-silica capillaries by photopo

174 SiHa cells, using a typical 15 cmx75 microm i.d. packed capillary column.

175 rodialysis membranes (3 mm lengthx200 microm i.d.) have been used to extract volatile analytes from a

176 e complexes are flowed through a 150-microm (i.d.) capillary cell and detected using a low-power He-N

177 A 50 microm (i.d.) x 38 cm (effective length) fused silica capillary

178 on rat mesenteric lymphatics (90-220 microm, i.d.) using servo-controlled wire- and pressure-myograph

179 (styrene-divinylbenzene) (PS-DVB), 10-microm-i.d. porous layer open tubular (PLOT) capillary columns

180 s have been determined for 25- and 10-microm-i.d. silica capillaries.

181 The reactor has been used with 100-microm-i.d. columns with insignificant effects (i.e., <3%) on p

182 retical plates for 75-microm- and 100-microm-i.d. separation capillaries are 1.6 x 10(5) and 2.5 x 10

183 capacities of approximately 10(3)) 15-microm-i.d. capillary liquid chromatography separations (i.e.,

184 y125-cm) and narrow (approximately 15-microm-i.d.) capillary, the four major proteins of the RBC, whi

185 ysis of a standard peptide using a 20-microm-i.d. capillary.

186 A single, 7-cm, 20-microm-i.d. fused-silica capillary (total volume, 70 nL), with

187 This work explores the use of 20-microm-i.d. polymeric polystyrene-divinylbenzene monolithic nan

188 ith an underivatized, 130-cm-long, 20-microm-i.d., 150-microm-o.d. fused-silica capillary and by moni

189 tomole levels using a 130-cm-long, 20-microm-i.d., 150-microm-o.d. underivatized fused-silica capilla

190 In a 25-microm-i.d. tube, the amount of ATP released from the RBCs incr

191 ry LC columns (25-microm i.d.) with 3-microm-i.d. integrated electrospray emitters interfaced to a qu

192 cles were obtained and packed into 30-microm-i.d. fused-silica capillary columns up to 50 cm in lengt

193 A single 30-microm-i.d. fused-silica capillary was used both as the reactio

194 -microm porous C18 particle-packed 50-microm-i.d. capillaries were used to speed the RPLC separations

195 capillary lengths (180 cm) with a 50-microm-i.d. capillary (24.5 cm effective capillary length), tot

196 rylate) monolith prepared within a 50-microm-i.d. capillary.

197 ith matrix flowing from a separate 50-microm-i.d. capillary.

198 The RPLC separations used 50-microm-i.d. fused-silica capillaries packed with submicrometer-

199 ample is deposited directly from a 50-microm-i.d. separation capillary onto the 19-mm ball that is ro

200 ormed on a quadrupole ion trap, a 500-microm-i.d. waveguide was used as a medium to transmit IR radia

201 a MPN film was obtained in a 2-m, 530-microm-i.d. deactivated silica capillary using gravity to force

202 oteolytic peptides for 14.9- and 29.7-microm-i.d. packed capillaries, respectively), the nanoLC/nanoE

203 nd again pressure on 25-, 50-, and 75-microm-i.d. capillaries are shown.

204 monolith was synthesized inside a 75-microm-i.d. capillary by photoinitiated copolymerization with w

205 sin I, the carbon fiber emitter in 75-microm-i.d. fused-silica tubing was shown to give ion current c

206 of up to 20-fold improvement over 75-microm-i.d. nanocolumns.

207 latinum wire was inserted into the 75-microm-i.d. separation capillary.

208 Larger (16-micron-i.d.) separation capillaries provide concentration detec

209 ersed-phase separation of peptides on a 1 mm i.d. column operating at flow rate of 50 microL/min.

210 mm were most effective when made with 2.1 mm i.d. tubing.

211 ed in series with a diol column, both 2.1 mm i.d. x 150 mm long, packed with 5-mum spherical silica-b

212 us, we constructed a tubular structure (1 mm i.d.) from aligned human mesenchymal cell sheets (hMSC)

213 A glass capillary (1.1 mm i.d.) packed with 3.4 mg of Carbopack X and 1.2 mg of Ca

214 An ACQUITY UPLC(R) BEH C18 (50 mm x 2.1 mm i.d., 1.7 mm particle size) column was employed.

215 (BEH) C18 reversed-phase column (50 x 2.1 mm i.d., 1.7-microm particle size) with gradient elution at

216 ersil C8 HyPurity Advance column (100x2.1 mm i.d., 3 microm) was used with a flow rate of 0.3 ml/min)

217 chieved on a Waters X-Terra C18 (50 x 2.1 mm i.d., 3.5 microm) analytical column with acetonitrile/wa

218 per, we compare a narrow-bore column (2.1-mm i.d.) to a conventional-bore column (4.6 mm i.d.) at ele

219 ocities by using narrow-bore columns (2.1-mm i.d.).

220 The modulator tube is 0.18 mm i.d. x 8 cm in length.

221 aphy (GC) open-tubular columns (OTC, 0.18 mm i.d., 20 m long, ~0.2 mum stationary film thickness) to

222 The capillary column ensemble (0.18-mm i.d. x 0.18-microm film thickness) consists of a 7.0-m l

223 ogenic water trap with narrow-bore (<0.20 mm i.d.) transfer lines, and a narrow i.d. open split to th

224 tly anchored to the inner walls of a 0.25 mm i.d. fused silica capillary to produce a sol-gel germani

225 al plates/m was obtained on a 10 m x 0.25 mm i.d. fused-silica capillary column.

226 However, with the same LC instrument, 3 mm i.d. columns as short as ~5 to 10 mm could be effectivel

227 low-field (47.5 mT) preclinical scale (38 mm i.d.) 2D magnetic resonance imaging (MRI).

228 When a 4.5 mm i.d. x 0.95 mm monolith disk containing anti-FITC antibo

229 With the use of packed microcolumns (<0.5 mm i.d.), essentially instantaneous heat transfer from the

230 The 20 muL min(-1) flow rate of 6 mm i.d. pumps with Nafion coated electrodes operate daily f

231 i.d.) to a conventional-bore column (4.6 mm i.d.) at elevated temperatures under conditions where th

232 alized for 75 muL samples placed within 7 mm i.d. standard cylindrical microwells.

233 low rate of 15 mL/min with a 5 cm by 4.6 mm (i.d.) column packed with 3 microns polystyrene-coated zi

234 ed columns (lengths 30, 50, 100, and 150 mm, i.d., 1 and 2.1 mm, all packed with Acquity UPLC, BEH-C

235 fraction was extracted in 180 ms by a 2.1-mm-i.d. sandwich microcolumn that contained a 1.1-mm layer

236 ure moves between three heat zones in a 1-mm-i.d., oil-filled capillary using a multielement scattere

237 A 14-m-long, 0.18-mm-i.d. column ensemble consisting of 7.0-m lengths of a tr

238 tandem ensemble of two 4.5-m-long x 0.25-mm-i.d. capillary columns with the first using a 0.50-micro

239 ation is performed with a 15-m-long, 0.25-mm-i.d. capillary using a 0.5-microm-thick film of nonpolar

240 A 12-m-long, 0.25-mm-i.d. tandem column ensemble consisting of 4.5-m dimethyl

241 tanyl was administered intradermally (1 mug, i.d.), in the vicinity of peripheral nociceptor terminal

242 d-dimension column was a 0.5 m long, 100 mum i.d. capillary with a poly(ethylene glycol) phase.

243 ncorporated a short capillary (5 cm x 15 mum i.d.) for the electrophoretic separation of analytes wit

244 nolithic capillary column (16.5 cm x 150 mum i.d.) synthesized from poly(ethylene glycol) diacrylate.

245 m single cells were separated using a 20 mum i.d. in-house-packed nanoLC column.

246 s of the RP analytical column down to 25 mum i.d. for an additional 2- to 3-fold improvement in perfo

247 to 7,000,000 theoretical plates in a 25 mum i.d. fused silica capillary.

248 GC x GC separations was a 6 m long, 250 mum i.d. capillary with a PDMS stationary phase, and the sec

249 t test mixture separated on a 30 m x 250 mum i.d. RTX-5 column with a LECO Pegasus III TOFMS.

250 fiber (50 mum of wall-thickness and 280 mum i.d.), this setup allowed for a continual renewal of the

251 10-port valve for compatibility with 30 mum i.d. nanoLC columns.

252 o previous efforts using larger bore (30 mum i.d.) LC columns coupled to a previous-generation Orbitr

253 It is demonstrated that 5 mum i.d. capillaries can be coated with mesoporous silica la

254 lts were obtained with a capillary of 50 mum i.d. x 50 cm effective length, sodium tetraborate 40 mM

255 y prepared conventional CE capillary (50 mum i.d., 363 mum o.d.).

256 total length fused-silica capillary (50 mum i.d., 80 mum o.d.) combined with refractive index (RI) d

257 te] monoliths were synthesized inside 75 mum i.d. capillaries by one-step UV-initiated copolymerizati

258 e synthesize polymer monoliths inside 75 mum i.d. capillaries, use these monoliths to assemble miniat

259 Each monolith in a 75 mum i.d. capillary is equivalent to several thousands of ope

260 ction windows was used with a 95 cm x100 mum i.d. capillary.

261 tic flow through an 11 cm (length) x 50 mum (i.d.) sampling capillary is introduced to a simple micro

262 and ethylene dimethacrylate inside a 100-mum-i.d. capillary.

263 The picoLC employs a 2-mum-i.d. open tubular column to reduce the sample input need

264 (<0.20 mm i.d.) transfer lines, and a narrow i.d. open split to the IRMS directly inserted into the c

265 pA in combination with LT-IIb(T13I), a novel i.d. adjuvant of the type II heat-labile enterotoxin fam

266 These results demonstrate the potential of i.d. vaccination with IpaB and IpaD to prevent Shigella

267 Immune T lymphocytes from the spleens of i.d. LVS-vaccinated WT or KO mice controlled intracellul

268 -inoculated mouse lung tissues from those of i.d.-inoculated and control mouse lung tissues.

269 y, mice immunized with LVS DeltacapB i.n. or i.d. and then challenged 6 weeks later by aerosol with 1

270 leptospiral challenge by either the i.p. or i.d. route.

271 persion across the open-tubular column (OTC) i.d..

272 IO mice, administration of MTII 100 microg q.i.d. i.p. markedly suppressed feeding during the first 4

273 MTII administration (100 microg q.i.d. i.p.) for 24 h results in similar weight loss but a

274 indicate that the more biologically relevant i.d. model of bubonic plague differs significantly from

275 ricted rat mesenteric small arteries (RMSAs, i.d. 200-300 microm) was studied using small vessel myog

276 age versus 474 micromol/kg/day once daily (s.i.d.).

277 cal Shwartzman reaction (LSR) after a single i.d. injection of LPS, whereas in the classic LSR, a sec

278 separation capillary, and a detachable small i.d. porous electrospray ionization (ESI) emitter was de

279 ical calculations indicate that even smaller i.d. columns can be used with little effect on chromatog

280 Suitable i.d. adjuvants are important to increase vaccine efficac

281 placebo (n=2), and the third cohort 40 mg t.i.d. (n=6) or placebo (n=2).

282 on one of two regimes of pindolol (2.5 mg t.i.d. and 5.0 mg t.i.d.) with PET and [11C]WAY-100635.

283 3) SRP plus metronidazole capsule (250 mg t.i.d. for one week).

284 The 5-mg t.i.d. regime achieved a modest (19%) but significant occu

285 e vast majority of clinical trials (2.5 mg t.i.d.) did not achieve a significant occupancy.

286 omized to receive baclofen (60 mg/d; 20 mg t.i.d.) or placebo.

287 y was not possible and mesalazine (1000 mg t.i.d.) was added to prednisolone (10.0 mg/d).

288 imes of pindolol (2.5 mg t.i.d. and 5.0 mg t.i.d.) with PET and [11C]WAY-100635.

289 glucosamine at standard doses (500 mg p.o. t.i.d.) in lean (n = 20) and obese (n = 20) subjects.

290 ed to compare addition of 5 mg of pindolol t.i.d. or placebo for 4 weeks to a steady paroxetine dose.

291 hain amino acids (222 mg/kg of body weight t.i.d.) (N=18) and those who received placebo (N=18) in th

292 suggest that i.n. IT is more effective than i.d. IT for the treatment of asthma.

293 We have reported that i.d. injection of plasmids encoding hsp70 and a suicide

294 the magnitude of CD4 T-cell responses in the i.d. group was indistinguishable from those in the other

295 nitude after the DNA vaccinations, while the i.d. group exhibited the responses of the least magnitud

296 cine was administered intranasally, with the i.d. route requiring 25-40 times lower doses.

297 ated twice with 20 mug of DNA plus Vaxfectin i.d., 100 mug of DNA plus Vaxfectin i.d., 100 mug of DNA

298 axfectin i.d., 100 mug of DNA plus Vaxfectin i.d., 100 mug of DNA plus Vaxfectin i.m. or 100 mug of D

299 In these studies, single nanotubes with i.d.'s of either 30 or 170 nm were investigated over a r

300 amma production, however, was seen only with i.d. and i.l. routes of administration, and no IL-4 resp